Conferences

ecancer travels so that you don't have to. Expore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

2016 Genitourinary Cancers Symposium

7 Jan 2016
Moscone West Building, 800 Howard Street, San Fransisco, United States of America
Entinostat and high-dose Interleukin 2 in renal cell carcinoma patients
Prof Roberto Pili - Indiana University, Indianapolis, USA
Entinostat and high-dose Interleukin 2 in renal cell carcinoma patients ( Prof Roberto Pili - Indiana University, Indianapolis, USA )
9 Jan 2016
Best of ASCO GU 2016 prostate cancer data
Prof Noel Clarke, Dr Heather Payne, Prof Peter Iverson
Best of ASCO GU 2016 prostate cancer data ( Prof Noel Clarke, Dr Heather Payne, Prof Peter Iverson )
8 Jan 2016
Gemcitabine plus cisplatin plus ipilimumab for metastatic urothelial cancer
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
Gemcitabine plus cisplatin plus ipilimumab for metastatic urothelial cancer ( Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA )
8 Jan 2016
Avelumab for metastatic urothelial carcinoma: JAVELIN trial
Dr Andrea Apolo - National Cancer Institute, Maryland, USA
Avelumab for metastatic urothelial carcinoma: JAVELIN trial ( Dr Andrea Apolo - National Cancer Institute, Maryland, USA )
8 Jan 2016
Subgroup analyses of METEOR; randomized phase III trial of cabozantinib vs evero...
Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France
Subgroup analyses of METEOR; randomized phase III trial of cabozantinib vs everolimus for RCC ( Prof Bernard Escudier - Institut Gustave-Roussy, Paris, France )
8 Jan 2016
Integrated genomic correlates of response to PD-1 inhibitor nivolumab in mRCC
Dr Guillermo de Velasco - Dana-Farber Cancer Institute, Boston, USA
Integrated genomic correlates of response to PD-1 inhibitor nivolumab in mRCC ( Dr Guillermo de Velasco - Dana-Farber Cancer Institute, Boston, USA )
8 Jan 2016
Discontinuing VEGF-targeted therapy for progression or toxicity affects outcomes...
Dr Guillermo de Velasco - Dana-Farber Cancer Institute, Boston, USA
Discontinuing VEGF-targeted therapy for progression or toxicity affects outcomes of second-line therapies in mRCC ( Dr Guillermo de Velasco - Dana-Farber Cancer Institute, Boston, USA )
8 Jan 2016
Impact of metformin on outcomes for metastatic renal cell carcinoma
Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA
Impact of metformin on outcomes for metastatic renal cell carcinoma ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )
8 Jan 2016
Comparing adjuvant radiotherapy plus chemo vs. adjuvant chemo following cystecto...
Dr Brian Baumann - University of Pennsylvania, Philadelphia, USA
Comparing adjuvant radiotherapy plus chemo vs. adjuvant chemo following cystectomy for bladder cancer ( Dr Brian Baumann - University of Pennsylvania, Philadelphia, USA )
8 Jan 2016
Molecular genetics of testicular cancer: What does the clinician need to know?
Dr Katherine Nathanson - University of Pennsylvania, Philadelphia, USA
Molecular genetics of testicular cancer: What does the clinician need to know? ( Dr Katherine Nathanson - University of Pennsylvania, Philadelphia, USA )
8 Jan 2016
New treatment options in metastatic prostate cancer
Dr Neal Shore and Dr Axel Merseburger
New treatment options in metastatic prostate cancer ( Dr Neal Shore and Dr Axel Merseburger )
8 Jan 2016
ASCO GU 2016: Highlights
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
ASCO GU 2016: Highlights ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
8 Jan 2016
Atezolizumab for platinum-treated locally advanced or metastatic urothelial carc...
Dr Jean Hoffman-Censits - Kimmel Cancer Center, Philadelphia, USA
Atezolizumab for platinum-treated locally advanced or metastatic urothelial carcinoma ( Dr Jean Hoffman-Censits - Kimmel Cancer Center, Philadelphia, USA )
8 Jan 2016
Healthcare and QoL burden of symptomatic skeletal events in CRPC with bone mets
Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA
Healthcare and QoL burden of symptomatic skeletal events in CRPC with bone mets ( Dr Rana McKay - Dana-Farber Cancer Institute, Boston, USA )
8 Jan 2016
Regular aspirin use may reduce risk of dying from prostate cancer
Dr Christophe Allard - Massachusetts General Hospital, Boston, USA
Regular aspirin use may reduce risk of dying from prostate cancer ( Dr Christophe Allard - Massachusetts General Hospital, Boston, USA )
8 Jan 2016
ASCO GU: Advances in prostate cancer from day one
Dr Axel Merseburger, Dr Eleni Efstathiou, Prof Karim Fizazi, Prof Nick James
ASCO GU: Advances in prostate cancer from day one ( Dr Axel Merseburger, Dr Eleni Efstathiou, Prof Karim Fizazi, Prof Nick James )
7 Jan 2016
Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer
Prof Eleni Efstathiou and Prof Nick James
Celecoxib with or without zoledronic acid for hormone-naïve prostate cancer ( Prof Eleni Efstathiou and Prof Nick James )
7 Jan 2016
Alisertib for pretreated urothelial cancer
Dr Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Alisertib for pretreated urothelial cancer ( Dr Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )
7 Jan 2016
Link between non-aspirin NSAID use and risk of developing renal cell cancer
Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA
Link between non-aspirin NSAID use and risk of developing renal cell cancer ( Dr Toni Choueiri - Dana Farber Cancer Institute, Boston, USA )
7 Jan 2016
Brentuximab vedotin as salvage therapy for men with relapsed germ-cell tumours
Dr Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Brentuximab vedotin as salvage therapy for men with relapsed germ-cell tumours ( Dr Andrea Necchi - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )
7 Jan 2016
Actionable targets in patients with cisplatin-resistant advanced germ cell tumou...
Dr Aditya Bagrodia - Memorial Sloan Kettering New York, USA
Actionable targets in patients with cisplatin-resistant advanced germ cell tumours ( Dr Aditya Bagrodia - Memorial Sloan Kettering New York, USA )
7 Jan 2016